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ABSTRACT
APOBEC3G (A3G), a host protein that inhibits HIV-1
reverse transcription and replication in the absence
of Vif, displays cytidine deaminase and single-
stranded (ss) nucleic acid binding activities. HIV-1
nucleocapsid protein (NC) also binds nucleic acids
and has a unique property, nucleic acid chaperone
activity, which is crucial for efficient reverse tran-
scription. Here we report the interplay between A3G,
NC and reverse transcriptase (RT) and the effect of
highly purified A3G on individual reactions that
occur during reverse transcription. We find that
A3G did not affect the kinetics of NC-mediated
annealing reactions, nor did it inhibit RNase H
cleavage. In sharp contrast, A3G significantly inhib-
ited all RT-catalyzed DNA elongation reactions with
or without NC. In the case of (2) strong-stop DNA
synthesis, the inhibition was independent of A3G’s
catalytic activity. Fluorescence anisotropy and
single molecule DNA stretching analyses indicated
that NC has a higher nucleic acid binding affinity
than A3G, but more importantly, displays faster
association/disassociation kinetics. RT binds to
ssDNA with a much lower affinity than either NC or
A3G. These data support a novel mechanism
for deaminase-independent inhibition of reverse
transcription that is determined by critical
differences in the nucleic acid binding properties
of A3G, NC and RT.
INTRODUCTION
Human APOBEC3G (A3G) is a host cytidine deaminase,
which was ﬁrst identiﬁed by Sheehy et al. (1) as the cellular
factor that blocks HIV-1 replication in the absence of the
viral Vif protein. Cellular expression of A3G results in its
incorporation into vif-deﬁcient HIV-1 particles, whereas
its presence in WT virions is dramatically reduced by Vif-
induced degradation via the ubiquitination-proteosome
pathway (2).
Initial studies suggested that the deamination activity
of A3G contributes to its antiviral activity and is
associated with G to A hypermutation (3–6). However,
more recent results indicate that a deaminase-independent
mechanism might also be involved in A3G’s antiviral
activity: (i) Deamination activity is not absolutely
correlated with antiviral activity against HIV-1 (7–15);
(ii) Several reports (though not all) indicate that hepatitis
B virus may be inhibited by A3G without signiﬁcant
detection of G to A hypermutation (16–18) and (iii) Other
APOBEC proteins block replication of mouse mammary
tumor virus (19) and several retrotransposons (14,20–24)
in the absence of editing activity.
Prior to the discovery of A3G, it was already known
that vif viruses produced in ‘nonpermissive’ cells
(PBMCs or certain T-cell lines, e.g. H9) were 100- to
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deﬁcient in their ability to complete reverse transcription
(28–31). Moreover, similar results were obtained in
endogenous reverse transcription assays (30,32,33).
More recent analysis of HIV-1-infected cells expressing
A3G or A3F has conﬁrmed the initial observations
(5,10,13,15,34–38).
Eﬃcient and speciﬁc reverse transcription depends on
the viral nucleocapsid protein (NC), which functions as a
nucleic acid chaperone (39–43). This means that NC can
catalyze nucleic acid conformational rearrangements
that lead to the most thermodynamically stable structures
(44). Like NC, A3G has two zinc ﬁnger domains and
binds nucleic acids (45). However, whereas A3G has a
strong preference for binding single-stranded (ss) nucleic
acids (6,12), NC binds ss or double-stranded (ds) RNA
and DNA (46) [for further information on NC’s nucleic
acid binding properties, see Ref. (47)]. The two proteins
also diﬀer in their eﬀects on virus replication: NC acts as
a positive factor, whereas A3G is an inhibitor in the
absence of Vif.
We previously reported the successful preparation of
highly puriﬁed, catalytically active A3G expressed in a
baculovirus system and demonstrated that the availability
of a pure protein (without contamination by other
proteins, either host or viral) was invaluable for rigorous
analysis of the biochemical properties of A3G (12).
In the course of this study, we unexpectedly found that
A3G does not interfere with NC binding to ssRNA (and
vice versa) (12). This suggested that inhibition of reverse
transcription by A3G is likely to be unrelated to an eﬀect
on NC chaperone function.
To test this hypothesis and to probe the mechanism
that might be involved, we took advantage of deﬁned
biochemical assay systems that we have developed over
the years for studies on viral DNA synthesis (48–51).
Thus, using our highly puriﬁed A3G as well as puriﬁed
NC and RT, we investigated the eﬀect of A3G on a series
of reconstituted reactions that occur during reverse
transcription. This allowed us to perform an independent
analysis of individual steps in the pathway, which is not
possible in cell-based systems. We found that A3G
inhibited all reverse transcriptase (RT)-catalyzed DNA
elongation reactions, but not RNase H activity or NC’s
ability to promote annealing. These observations could be
explained by critical diﬀerences in the binding properties
of NC, A3G and RT, as measured by single-molecule
DNA stretching and ﬂuorescence anisotropy (FA).
Our ﬁndings are unique and provide strong support for
a novel mechanism that could account for the observed
deaminase-independent A3G-mediated antiviral activity.
MATERIALS AND METHODS
Materials
Puriﬁed tRNA
Lys
3 from human placenta was obtained
from Bio S&T (Lachine, Quebec, Canada). DNA and
RNA oligonucleotides were purchased from Lofstrand
(Gaithersburg, MD), Integrated DNA Technologies
(Coralville, IA), Oligos Etc., Inc. (Wilsonville, OR).
[g-
32P]ATP (3000Ci/mmol) and [a-
32P]dCTP (6000Ci/
mmol) were purchased from GE Healthcare (Piscataway,
NJ). HIV-1 RT was obtained from Worthington
Biochemical Corp. (Lakewood, NJ). Calf intestinal
phosphatase, T4 polynucleotide kinase, and Vent DNA
polymerase were obtained from New England Biolabs
(Beverly, MA). SUPERaseIn, an RNase inhibitor,
was purchased from Ambion, Inc. (Austin, TX).
Recombinant wild-type HIV-1 NC (55-amino-acid form)
was a generous gift from Dr Robert Gorelick and was
prepared as described previously (52,53). Recombinant
enzymatically active A3G and the deaminase-deﬁcient
A3G mutant (C291S) were expressed in a baculovirus
expression system and puriﬁed as previously described
(12). A3G preparations were conﬁrmed to be free from
contamination with RNases (data not shown) and no
RNA degradation was apparent in any of the experiments
(e.g. see Figure 2A).
Methods
Plasmid construction. All plasmid sequences were
derived from the HIV-1 pNL4-3 clone (54). Plasmid
pUL (viral insert from nt 566 to 1419) was constructed
from the previously described pRUG plasmid (51).
Preparation of RNA. The DNA templates for in vitro
RNA transcription were derived from plasmid pRUG [for
transactivation response element (TAR) RNA, nucleo-
tide(s) (nt) 1–59] or pUL (for RNA UL244, nt 113–244).
DNA fragments containing both the T7 promoter and the
DNA sequence equivalent to the desired vRNA were
ampliﬁed by PCR using Vent DNA polymerase and the
following primers: forward primer (50-ccaatgcttaatcagt-
gaggc), located at the start of the amp gene in pUL; reverse
primers, 50-gtcctgcgtcgagagatc (RNA UL244) and
50-gggttccctagttagccaga (TAR RNA). The DNA frag-
ments were gel-puriﬁed and transcribed using an Ambion
MEGAscript kit (Ambion Inc., Austin, TX). Gel-puriﬁed
RNAs were dephosphorylated by calf intestinal phos-
phatase and were then labeled at their 50 ends with
[g-
32P]ATP, using T4 polynucleotide kinase (55).
Unincorporated nucleotides were removed by passing
the reaction mixture through NucAway Spin Columns
(Ambion). RNA 244 (51) and acceptor RNA 148 (49)
were prepared as described.
Reverse transcription assays. Reaction components are
given for 20ml unit reactions, which were scaled up as
needed. SUPERaseIn at a ﬁnal concentration of 0.5U/ml
was added to all RNA-containing reaction mixtures.
Incubation/preincubation was always at 378C. Six percent
native or denaturing polyacrylamide gels were used for
annealing or extension assays, respectively, except as
noted. Radioactivity was quantiﬁed by using a Typhoon
PhosphorImager and ImageQuant software.
tRNA
Lys
3 annealing to viral RNA (vRNA). Reaction
mixtures contained buﬀer (50mM Tris–HCl (pH 8.0),
75mM KCl, 0.1mM MgCl2, 1mM DTT), 0.2pmol
of puriﬁed human placental tRNA
Lys
3 and 0.1pmol of
50 32P-labeled RNA UL244 and were incubated in the
Nucleic Acids Research, 2007, Vol. 35, No. 21 7097absence or presence of A3G (80nM) with or without HIV-
1 NC (7nt/NC, 0.2mM). Prior to loading on the gel, the
samples were treated with Proteinase K (0.5mg/ml).
( )Strong-Stop DNA [( ) SSDNA] synthesis. Template
RNA 244 (0.1pmol) and 0.1pmol each of human tRNA
Lys
3
or
32P-labeled D18 primer, [complementary to the 18-nt
primer-binding site (PBS)] were heat-annealed as described
(51). A3G or heat-denatured (hd)A3G was then added to
buﬀerdesignatedas‘reactionbuﬀer’(50mMTris–HCl(pH
8.0), 75mM KCl, 7mM MgCl2, 1mM DTT) and the
mixture was preincubated for 5min. Primer extension was
initiatedbyaddingHIV-1RT(0.1pmol)and50mMeachof
dATP, dTTP and dGTP plus 10mCi of [a-
32P]dCTP
(tRNA
Lys
3 )o r5 0mM each of all four dNTPs (D18).
Annealing and minus-strand transfer. Minus-strand
annealing was performed as described previously (56) in
the presence or absence of A3G (80nM) with or without
HIV-1 NC (3.5nt/NC, 0.4mM). For minus-strand transfer
assays, reaction mixtures contained the components
present in annealing reactions as well as HIV-1 RT
(0.4pmol), all four dNTPs (each at 50mM), and 1mM
MgCl2.
Initiation of plus-strand DNA synthesis. The assay was
performed using a modiﬁed version of a previous protocol
(57). Brieﬂy, the 15-nt polypurine tract (PPT) primer
(0.2pmol) was heat-annealed to a 35-nt minus-strand
DNA template (0.1pmol) and the hybrid was preincu-
bated with or without A3G (80nM) for 5min in reaction
buﬀer (see above). DNA synthesis was initiated by adding
HIV-1 RT (0.4pmol), all four dNTPs (each at 0.5mM),
and [a-
32P]dCTP (20mCi), which results in an internally
labeled DNA product. Samples were loaded on a 15%
denaturing gel. Since RNase H cleavage removes the
annealed 15-nt PPT RNA, the DNA product is 20nt.
Plus-strand transfer. The assay was performed as
described previously (50) except that the ﬁnal concentra-
tions of 50 32P-labeled (+) SSDNA donor (50nt) and
minus-strand DNA acceptor (48nt) were 5nM, all four
dNTPs were at 50mM each, and HIV-1 RT was 20nM.
Reactions were incubated in the presence or absence of
NC (3.5nt/NC, 0.14mM), with or without A3G (80nM).
Single molecule DNA stretching. Puriﬁed bacteriophage
lambda DNA (48500bp) was labeled on its 30 ends with
biotin and single DNA molecules were captured between
two streptavidin-coated, 5mm diameter polystyrene beads
using a dual beam optical tweezers instrument (58,59).
The 16.5mm contour length DNA molecule was stretched
in 100nm steps using a piezoelectric ﬂexure translation
stage (Melles Griot, Carlsbad, CA) to reveal the DNA
force-extension curve, as described previously (58). After
stretching a single DNA molecule in DNA stretching
buﬀer (10mM HEPES, pH 7.5, 50mM Na
+,a t2 0 8C),
and verifying that a single molecule was present, the buﬀer
solution was exchanged for a solution containing the same
buﬀer with a ﬁxed protein concentration. The protein
exchange procedure was then repeated for diﬀerent
protein concentrations in order to determine the eﬀect
of protein on DNA stretching behavior. The transition
width and hysteresis were analyzed as described previously
(60) for 3 or more DNA molecules.
FA experiments. Equilibrium binding of HIV-1 NC,
HIV-1 RT and human A3G to a 6-carboxyﬂuorescein
(FAM)-labeled 20-nt ssDNA oligonucleotide
(50-FAM-JL587D, 50FAM-CTTCTTTGGGAGTGAAT
TAG-30) was examined using FA. The HPLC-puriﬁed
oligonucleotide 50-FAM-JL587D was purchased from
TriLink Biotechnologies (San Diego, CA). FA measure-
ments were performed on an Analyst AD plate reader
system (Molecular Devices, Sunnyvale, CA) using
Corning 3676 low-volume 384-well black non-binding
surface polystyrene plates. Reaction mixtures contained
20nM 50-FAM-JL587D, varying concentrations of NC,
RT or A3G, and buﬀer consisting of 50mM Tris–HCl
(pH 8.0), 75mM KCl, 7mM MgCl2 and 1mM DTT.
Samples were excited at 485nm and the emission
intensities at 530nm from the parallel and perpendicular
planes were measured. Apparent equilibrium dissociation
constants (Kd) were determined by plotting the FA signal,
A, as a function of protein concentration, C. The data
were ﬁt assuming 1:1 oligomer:protein binding using the
expression (61,62):
AðCÞ¼
AF þ    ABR   AF ðÞ
   R   1 ðÞ þ 1
where
 ¼
1
2D
  D þ C þ Kd  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
D þ C þ Kd ðÞ
2 4C   D
q   
is the fraction of oligonucleotides bound, D is the
oligonucleotide strand concentration, and AB and AF are
the anisotropy values of the fully bound and unbound
oligonucleotides, respectively. R is the ratio of the
ﬂuorescence intensity of saturated bound oligonucleotide
relative to free oligonucleotide, which accounts for
changes in ﬂuorescence intensity upon protein binding
(46,47,61).
RESULTS
Effect of A3G on primer placement and (2) SSDNA
synthesis
To determine the mechanism by which A3G inhibits
HIV-1 DNA synthesis, we analyzed the eﬀect of A3G on
single steps in the reverse transcription pathway (Figure 1)
(43). Annealing and DNA synthesis were assayed in a
series of reconstituted model systems. Our goal was to
determine whether A3G interfered with the nucleic
acid chaperone activity of NC, the catalytic activity
of RT, or both during these reactions. Note that in
most of the assays, the concentration of A3G did
not exceed 80nM, since A3G precipitates at high
concentrations (12).
To evaluate the eﬀect of A3G on the ﬁrst step in
reverse transcription (primer placement), we investigated
7098 Nucleic Acids Research, 2007, Vol. 35, No. 21the time course of NC-dependent annealing of human
tRNA
Lys
3 to the PBS in a short vRNA template
(RNA UL244) (Figure 2A and B). In the absence of NC
and A3G, no annealing was detected. As shown in
Figure 2B, the rates of annealing in the presence of NC
were similar for reactions with and without A3G and the
end point values at 64min were 70% and 66%,
respectively. Addition of NC and hdA3G resulted in a
slightly enhanced rate of annealing, but the end point
value was very close to the values with and without native
A3G. These results demonstrate that A3G did not
interfere with NC-mediated formation of the vRNA–
tRNA complex.
Primer placement is followed by extension of tRNA
Lys
3
and synthesis of (2) SSDNA (Figure 1, steps 1 and 2). To
measure extension alone, the tRNA was ﬁrst heat
annealed to the vRNA 244 template (51); the (2)
SSDNA product formed by addition of RT was internally
labeled (Figure 2C) (51). In the absence of A3G (lane 1) or
in the presence of hdA3G (lanes 2–4), equivalent amounts
of the 258-nt full-length product [(2) SSDNA attached to
tRNA
Lys
3 ] and pause products (including the initial +1,
+3 and +5 DNAs) were detected. However, in the
presence of increasing amounts of native A3G (20–80nM)
(lanes 5–7), the amounts of fully extended product and
pause products were greatly reduced; with 80nM A3G,
only the +1 and +5 DNAs could be detected (lane 7).
Furthermore, some of the pause products observed in
the presence of A3G diﬀered from those made in the
absence of the inhibitor (compare lanes 2–4 with lanes
5 and 6). Taken together, these results indicate that native
A3G strongly inhibited tRNA-primed (2) SSDNA
synthesis.
To investigate the kinetics of (2) SSDNA synthesis
in the presence of increasing amounts of A3G, we used
50 32P-labeled D18 in place of tRNA (Figure 3A).
This allowed us to obtain quantitative data, which were
plotted as the percent of (2) SSDNA in total DNA
products [% (2) SSDNA] versus Time (Figure 3B).
In accord with the tRNA experiment Figure 2C), A3G
reduced (2) SSDNA synthesis in a dose-dependent
manner (Figure 3A and B). For example, at 64min,
the relative amount of (2) SSDNA synthesized in the
80nM reaction was decreased by 24-fold compared with
the minus A3G value. In addition, as also shown in
Figure 2C, we observed changes in the pausing pattern in
A3G-containing reactions, which were accentuated with
increasing concentrations of A3G (Figure 3A). Interest-
ingly, mapping these sites on the RNA 244 template
structure (51) indicated that the pause sites occurred near
or within ss regions in the template (see Figure 3C, which
was derived from the gel data in Figure S1). This is
consistent with A3G’s well-documented, strong preference
for binding to ss nucleic acids (6,12).
The data in Figures 2 and 3 demonstrate that A3G
dramatically suppressed (2) SSDNA synthesis primed
by either tRNA
Lys
3 or D18. The results with D18 also
suggest that the reduction of tRNA-primed (2) SSDNA
synthesis by A3G was not due to an altered conﬁguration
of the tRNA/vRNA initiation complex. Interestingly,
when 6-fold less RNA template was used, 20nM of A3G
could completely inhibit (2) SSDNA synthesis (data not
shown). This indicates that A3G inhibition of (2) SSDNA
synthesis is dependent on the ratio of A3G:RNA.
It was also of interest to determine whether deaminase
activity is required for the A3G inhibitory eﬀect on
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+
−
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Figure 1. Schematic diagram of the events in reverse transcription.
Step 1. Reverse transcription is initiated by a cellular tRNA primer
(tRNA
Lys
3 , in the case of HIV-1), following annealing of the 30 18nt of
the tRNA to the 18-nt PBS near the 50 end of the genome. RT catalyzes
synthesis of (2) SSDNA, which contains copies of the R sequence and
the unique 50 genomic sequence (U5). Step 2. As the primer is extended,
the RNase H activity of RT degrades the genomic RNA sequences that
have been reverse transcribed. Step 3. (2) SSDNA is transferred to the
30 end of vRNA (minus-strand transfer). Step 4. Elongation of minus-
strand DNA and RNase H degradation continue. Plus-strand synthesis
is initiated by the 15-nt PPT immediately upstream of the unique
30 genomic sequence (U3). Step 5. RT copies the u3, u5 and r regions in
minus-strand DNA, as well as the 30 18nt of the tRNA primer, thereby
reconstituting the PBS. The product formed is termed (+) SSDNA.
Step 6. RNase H removal of the tRNA and PPT primers from minus-
and plus-strand DNAs, respectively. Step 7. Plus-strand transfer,
facilitated by annealing of the complementary PBS sequences at the
30 ends of (+) SSDNA and minus-strand DNA, is followed by
circularization of the two DNA strands and displacement synthesis.
Step 8. Minus- and plus-strand DNAs are elongated, resulting in a
linear dsDNA with a long terminal repeat (LTR) at each end. vRNA is
shown by an open rectangle and minus-and plus-strand DNAs are
shown by black and gray rectangles, respectively. The tRNA primer is
represented by a short open rectangle (30 18nt of the tRNA) attached
to a ‘clover-leaf’ (remaining tRNA bases). Minus- and plus-strand
sequences are depicted in lower and upper case, respectively. The very
short white rectangles represent fragments produced by RNase
H cleavage of genomic RNA. Adapted from reference (43) with
permission from Elsevier.
Nucleic Acids Research, 2007, Vol. 35, No. 21 7099(2) SSDNA synthesis. To address this question, we used
puriﬁed deaminase-deﬁcient A3G C291S protein (12)
and then compared the eﬀect of WT A3G or C291S on
D18-primed (2) SSDNA synthesis. As shown in Figure 4,
the rates and extents of (2) SSDNA synthesis in the
presence of WT or mutant A3G were virtually the same,
in accord with the observation that WT and C291S
proteins have similar Kd values for binding to ss nucleic
acids (12). The data of Figure 4 are signiﬁcant and
demonstrate that the inhibitory eﬀect of A3G on (2)
SSDNA synthesis is independent of A3G deaminase
activity in our assay system.
Effectof A3G on minus-strandtransfer reactions
Synthesis of a full-length minus-strand copy of the vRNA
genome is achieved by transfer of (2) SSDNA to the
30 end of vRNA (‘acceptor RNA’) followed by
RT-catalyzed extension of the annealed DNA (Figure 1,
step 3). This process (minus-strand transfer) is facilitated
by base pairing of the complementary repeat regions at
the 30 ends of the nucleic acid substrates and is dependent
on RNase H cleavage of vRNA sequences annealed
to (2) SSDNA (43).
In Figure 5A, we show the time course of RNase H
cleavage with the heat-annealed 59-bp TAR RNA/DNA
hybrid, which was incubated with and without NC, in the
absence or presence of A3G. Reactions containing A3G
appeared to have slightly faster cleavage rates. However,
the overall cleavage pattern was the same under all four
conditions. These results indicated that A3G does not
interfere with RNase H cleavage and is consistent with
A3G’s limited ability to bind to an RNA–DNA hybrid
(6,12).
To assay the eﬀect of A3G on minus-strand transfer,
we ﬁrst measured NC-mediated annealing using DNA
128 and acceptor RNA 148 (see schematic diagram in
Figure 5C) in the absence or presence of A3G (Figure 5B).
NC is required to transiently destabilize the complemen-
tary TAR RNA and DNA structures within the repeat
region, before hybrid formation can occur (43).
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Figure 2. Eﬀect of A3G on tRNA
Lys
3 -primed (2) SSDNA synthesis. (A) Time course of tRNA
Lys
3 annealing to RNA UL244. Reactions were
performed in the absence or presence of NC and A3G, as indicated by the headings at the top of the gel. The positions of the RNA UL244 template
and the annealed RNA duplex are shown on the right. (B) The percentage of annealed product was calculated by dividing the amount of annealed
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(lane 1) or presence of hdA3G (lanes 2–4) or A3G (lanes 5–7). The positions of (2) SSDNA and initial pause products at bases +1, +3 and +5 are
shown on the right. A3G concentrations: lane 1, 0nM; lanes 2 and 5, 20nM; lanes 3 and 6, 40nM; lanes 4 and 7, 80nM.
7100 Nucleic Acids Research, 2007, Vol. 35, No. 21Interestingly, A3G had only a minimal eﬀect on annealing
in the presence of NC. The rates were fairly similar with
and without A3G and there was only a small reduction
(11%) in the extent of the reaction when A3G was added.
In a control reaction, we found that the extent of
annealing minus NC, plus A3G was  10% (data not
shown), in accord with the value obtained in the absence
of NC and A3G (63).
We also assayed minus-strand transfer with the
complete system, which depends upon both annealing
and RT-catalyzed elongation reactions (Figure 5C).
The percent of total DNA present as the 182-nt strand
transfer product (% Transfer Product) was quantiﬁed
and plotted versus Time (Figure 5D). As we showed
previously (49,64,65), NC signiﬁcantly enhanced minus-
strand transfer. However, when A3G was added,
NC-mediated strand transfer was dramatically reduced
(Figure 5D). Note that in the absence of NC, the amount
of transfer product made was extremely small and little
eﬀect of A3G was observed.
Viewed collectively, the results of Figure 5 strongly
suggest that A3G inhibited minus-strand transfer by
blocking RT-catalyzed DNA elongation. In contrast,
A3G did not signiﬁcantly interfere with NC-facilitated
annealing of (2) SSDNA to acceptor RNA.
These ﬁndings parallel the results obtained for primer
placement (Figure 2A and B) and tRNA-primed synthesis
of (2) SSDNA (Figure 2C).
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transfer
While elongation of minus-strand DNA is being com-
pleted, the PPT RNA primer initiates synthesis of a short
DNA termed (+) SSDNA (Figure 1, steps 4 and 5) (43).
To determine whether A3G interferes with this step, we
used a simple oligonucleotide assay that was previously
developed in our laboratory (48,57). The 15-nt PPT was
heat-annealed to a 35-nt minus-strand DNA template and
the hybrid was then incubated with RT, which catalyzed
the extension and subsequent removal of the PPT. The
amount of 20-nt DNA product formed in reactions with
and without A3G was quantiﬁed and plotted (Figure 6A).
The results demonstrated that A3G reduced both the
rate and extent of (+) SSDNA synthesis by 2- to 3-fold.
The eﬀect of A3G on this reaction was lower than what we
observed for (2) SSDNA synthesis (Figure 3A and B) or
minus-strand transfer (Figure 5D). This is expected since
long templates were used for those assays. By contrast,
in the experiment shown in Figure 6A, only one or at most
two molecules of A3G can bind to the available 20-nt ss
region in the template (12,66). Nevertheless, it is
clear from the data that A3G was also able to inhibit
RNA-primed DNA-dependent DNA polymerization
by RT.
The plus-strand transfer reaction, like minus-strand
transfer, consists of two steps: (i) NC-mediated annealing
of the complementary PBS sequences in (+) SSDNA and
minus-strand acceptor DNA; and (ii) RT-catalyzed
elongation of both the plus- and minus-strand
DNAs to yield a double-stranded DNA product
(Figure 1, steps 6–8) (43). In our assay, only the
plus-strand
32P-labeled 80-nt DNA is detected. In the
absence of A3G, NC stimulated plus-strand transfer by
3-fold (Figure 6B), as reported previously (50). When
A3G was added, reduction of synthesis was observed
beginning at 10–15min (e.g. at 15min, by  4-fold),
whereas the extent of the reaction at 120min was
decreased by 2-fold. These results showed that A3G
inhibited DNA-dependent DNA polymerization.
Taken together, the in vitro data demonstrate that A3G
interfered with all of the elongation reactions catalyzed
by RT. In contrast, A3G was shown to have virtually
no inhibitory eﬀect on NC-mediated annealing reactions.
Single molecule DNA stretching andFA-binding
measurements
In an eﬀort to understand these results, the nucleic acid
binding properties of A3G, NC and RT were investigated
using single molecule DNA stretching and FA.
When optical tweezers are used to stretch single
DNA molecules by applying forces approaching 60pN
(Figure 7), a force-induced melting transition occurs,
in which dsDNA is converted to ssDNA (59). In the
absence of protein, this transition occurs over a very
narrow force range due to the cooperative melting of
DNA. Saturating levels of HIV-1 NC result in a signiﬁcant
increase in the width of the force-induced melting
transition (46), which correlates with NC’s relatively
eﬃcient chaperone activity. In addition, the reversibility
of DNA stretch/relax curves in the presence of NC
(i.e., DNA stretch curves show very little hysteresis),
suggests that NC has a fast nucleic acid binding on/oﬀ rate
and is therefore capable of rapidly switching between
dsDNA and ssDNA bound states (60).
To probe the nucleic acid binding properties of A3G,
we stretched single lambda DNA molecules in the
presence of varying amounts of A3G (Figure 7A; data
not shown) and characterized the transition width and
hysteresis. The transition width increased from
3.7 0.2pN in the absence of protein to 18.3 2.4pN at
protein saturation ( 90nM A3G and above).
Examination of the stretching and relaxation curves
showed that there was signiﬁcant hysteresis (Figure 7A),
which increased with A3G concentration, reaching a value
of iGhysteresis=0.56 0.02kcal/mol per bp at 150nM
A3G, as compared to iGhysteresis=0.22 0.06kcal/mol
per bp for saturated HIV-1 NC binding (Figure 7B) (60).
The greater hysteresis in the presence of A3G reﬂects the
inability of DNA to reanneal due to the presence of
bound protein, which dissociates more slowly than the
relaxation step time of  1s. In other experiments, RT
was found not to have any measurable eﬀect on
lambda DNA stretching (Wang,F. and Williams,M.C.,
unpublished data).
The apparent binding aﬃnities of HIV-1 NC, RT
and human A3G to a 20-mer ssDNA oligonucleotide,
50-FAM-JL587D, are given in Table 1 (also see Figure S2).
HIV-1 NC binds to the 20-mer DNA with an approxi-
mately 3-fold greater aﬃnity than human A3G.
Both A3G and HIV-1 NC bind ssDNA with a signiﬁ-
cantly higher aﬃnity (8- and 22-fold, respectively) than
HIV-1 RT. These studies suggested that A3G should
compete very eﬀectively with RT for binding to ssDNA,
but would not readily displace NC. Taken together
with the stretching data, these results help to explain
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Nucleic Acids Research, 2007, Vol. 35, No. 21 7103why A3G inhibits RT-catalyzed elongation reactions, but
fails to impact NC-mediated annealing.
DISCUSSION
Previous studies demonstrated that A3G inhibits reverse
transcription during infection with vif HIV-1 (28–31),
with eﬀects on synthesis of both early and late products
(5,10,13,15,35–37). In the present study, for the ﬁrst time,
we show how A3G aﬀects each individual step in reverse
transcription (Figure 1), using a series of well-deﬁned,
reconstituted assay systems and highly puriﬁed A3G,
RT and NC proteins. The results demonstrate that A3G
inhibits elongation by HIV-1 RT directly, and not by
blocking NC’s nucleic acid chaperone activity (43). These
ﬁndings are consistent with our previous result showing
that NC and A3G do not compete for binding to RNA
(12) and taken together, represent strong evidence that
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Table 1. Apparent binding aﬃnities of HIV-1 NC, HIV-1 RT and A3G
to 20-mer DNA oligonucleotide (50-FAM-JL587D)
Kd (nM)
a
HIV-1 NC 84.1 7.8
HIV-1 RT 1840 390
A3G 238 95
aKd values were determined from three independent experiments. The
error determinations represent the standard deviation.
7104 Nucleic Acids Research, 2007, Vol. 35, No. 21at a physical and functional level, NC and A3G do not
interfere with each other’s activities.
More speciﬁcally, we report that A3G inhibits (2)
SSDNA and (+) SSDNA synthesis, minus- and
plus-strand DNA transfer, and elongation of minus- and
plus-strand DNAs. Using a deaminase-deﬁcient A3G
mutant, we also show that (2) SSDNA synthesis was
inhibited in the absence of A3G’s enzymatic activity
(Figure 4). Additionally, during (2) SSDNA synthesis
in the presence of A3G, we ﬁnd that RT pauses at
unique sites, which map to bases in or near ss regions in
the RNA template structure (Figure 3C; also see
Figure S1), consistent with A3G’s preference for binding
to ss nucleic acids (6,12). Since a direct interaction
between A3G and RT could not be detected in pull-
down assays (data not shown), the results further suggest
that A3G binding to the template physically blocks
RT movement along the template. It should be noted
that A3G has a more profound eﬀect on DNA-primed
DNA polymerase activity than the ss-binding protein
T4 gene 32. Thus, in a primer extension assay with a DNA
template, gene 32 protein inhibited minus-strand
DNA synthesis at a concentration of 400 nM. In contrast,
an A3G eﬀect was already observed at a concentration of
12.5 nM and by 50 nM, the DNA product was no longer
detectable (data not shown).
Systematic study of A3G inhibition of individual
reverse transcription reactions is not amenable to inves-
tigation with more complex cell-based assays. However,
PCR analysis has indicated that during infection,
A3G inhibits synthesis of late DNA products to a greater
extent than early products (15,35,37). Conceivably,
successive inhibition at each step has a cumulative eﬀect.
Recently, Guo et al. (35) showed that reduction of early
reverse transcripts in A3G-expressing cells infected with
vif virions is correlated with decreased tRNA priming
in vitro. The authors suggested that an NC–A3G
interaction might be inhibiting viral DNA synthesis.
However, it was not determined whether A3G aﬀected
annealing and/or subsequent tRNA extension. In a new
in vitro study, this group reports that in the presence of
NC, A3G reduced tRNA
Lys
3 annealing by a little less
than 2-fold (67). The reason for the diﬀerence between
these results and our data showing that A3G does not
inhibit NC-mediated primer placement (but has a strong
eﬀect on primer extension) (Figures 2 and 3) in all
likelihood reﬂects signiﬁcant diﬀerences in the experimen-
tal conditions for annealing with respect to the nt/NC
ratio and the solution ionic strength.
Recently, it has been reported that A3G (15,37) and
A3F (15) inhibit HIV-1 integration as well as reverse
transcription. A3G and A3G C291S could each be
speciﬁcally coimmunoprecipitated with NC and integrase
(IN) present in HIV-1 vif virions; coimmunoprecipita-
tion of A3F with virion-associated IN could also be shown
(15). Sequence analysis of 2-LTR circle junction clones
from unintegrated DNA synthesized in the presence of
A3G showed that in some cases, DNA at the U5 end had
an additional 6 RNA bases derived from the 30 terminus of
tRNA
Lys
3 . This suggests that A3G causes a defect in the
tRNA removal step that limits plus-strand transfer and
ultimately integration (37). Since we present deﬁnitive
data showing that A3G does not inhibit RNase H
cleavage of RNA in a preformed hybrid (Figure 5A), we
suggest that the aberrant cleavage observed in vivo results
from A3G binding to site(s) on the tRNA primer and/or
the ssDNA template, thereby interfering with synthesis of
plus-strand DNA (Figure 6A) and formation of a proper
substrate for tRNA removal. Based on their results, Mbisa
et al. (37) have made a similar proposal.
It was of interest to determine whether the A3G
concentrations in the present study were within the
physiological range. A recent report showed that only
7(  4) molecules of A3G per virion are incorporated into
vif-deﬁcient HIV-1 produced from human PBMCs,
indicating that only a few molecules of A3G are suﬃcient
to inhibit HIV-1 replication (68). Interestingly, even the
highest concentrations of A3G used in our experiments
(up to 80 nM) are well below the estimated concentration
of A3G in the virion (13 8mM). This value was obtained
by assuming that the virus is a sphere of radius 60nm (69).
Despite the high estimated concentration of A3G in
the virus, the expected ratio of A3G:total nt of genomic
RNA in vivo is much lower than the ratio that is
typically used in vitro. However, RNA is highly folded
and rarely ss (39). Indeed, the vast majority of vRNA is
likely to be involved in secondary and tertiary interactions
(70–72). Since A3G binds poorly to dsRNA (6,12),
the eﬀective ratio of A3G:ss nt in vivo is higher than
predicted on the basis of total nt of RNA. Thus, the
preferential binding of A3G to ssRNA (6,12) and the
slow rate of A3G dissociation (Figure 7) could still result
in A3G-induced inhibition of reverse transcription
during infection.
The interpretation of the results presented here follows
from our studies on the nucleic acid binding properties
of NC, A3G and RT. Thus, the DNA stretching data in
the presence of A3G show an increase in the force-induced
melting transition width, suggesting that it is capable
of binding to both ss and dsDNA. However, relative to
NC, considerably higher concentrations of A3G are
required to observe changes in the shape of the DNA
stretching curve. Moreover, in sharp contrast to the small
hysteresis observed with NC (Figure 7B), which decreases
with increasing protein concentration (60), signiﬁcant
hysteresis is observed with A3G (Figure 7A). In this
case, the amount of hysteresis increases when the
protein concentration is elevated (data not shown).
Similar behavior is observed with the ssDNA-binding
protein T7 gene 2.5 (73), whose primary role in DNA
replication is to stabilize ssDNA.
The DNA stretching results indicate that A3G binds
preferentially to ssDNA and is unable to rapidly switch
between binding to ssDNA and dsDNA. This ﬁnding
can help to explain A3G’s inhibition of reverse transcrip-
tion, which requires rapid access of RT to the ssDNA or
RNA template. Similarly, the fact that HIV-1 NC does
not interfere with DNA synthesis is consistent with
its ability to rapidly adjust to diﬀerent binding states.
The stretching data complement the FA–binding measure-
ments, which show that the ssDNA binding order of the
three proteins is NC>A3G>>RT (Table 1; Figure S2).
Nucleic Acids Research, 2007, Vol. 35, No. 21 7105Taken together, these data explain why NC is not readily
displaced by A3G.
A major issue in research on A3G’s antiviral eﬀect is the
question of whether this activity is deaminase-dependent
or -independent (or both), but there is still no clear
consensus. There are data favoring the dependent
mechanism, as shown in several studies of G to A
hypermutation (3,4,6) and in some reports on reverse
transcription in vif HIV-1-infected cells (15,37).
However, there is also accumulating evidence indicating
that both types of mechanisms might be involved in
A3G’s eﬀect on reverse transcription in vivo (13,15). Our
studies do not exclude a requirement for editing, but based
on biochemical and biophysical analysis, provide support
for a novel molecular mechanism that could account
for deaminase-independent inhibition of reverse transcrip-
tion and virus replication that is observed in vivo.
In summary, our ﬁndings demonstrate for the ﬁrst time
that A3G can inhibit RT-catalyzed elongation in a
deaminase-independent manner without interfering with
NC-mediated chaperone activity. These results suggest
that A3G has an intrinsic eﬀect on viral DNA synthesis,
which is independent of the replication steps following
reverse transcription. Interplay of the equilibrium and
kinetic diﬀerences between HIV-1 NC, A3G and RT
with respect to their nucleic acid binding interactions
is likely to be a major determinant of deaminase-
independent A3G inhibition of RT-catalyzed DNA
extension.
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